Polyclonal and Monoclonal Antibodies to TPH1 and TPH2

Case ID:
07-824

This technology is a set of antibodies that is used with immunohistochemistry techniques to differentiate between tryptophan hydroxylase 1 and 2, enabling scientists to study how the two enzymes are differentially regulated.

 

Background & Unmet Need:

The tryptophan hydroxylase 1 and 2 (TPH1 and TPH2) genes encode enzymes in serotonin biosynthesis.  Variants in both genes have been implicated in several neuropsychiatric disorders and personality traits.  Prior to the discovery of TPH2 in 2003, it was thought that serotonin levels in the central nervous system were regulated by serotonin synthesis in the peripheral tissues, with TPH1 as the gene driving that mechanism.  The ability to differentiate between the two enzymes would allow scientists to study their different regulation mechanisms.

 

Technology Description:

WSU researchers have developed a group of monospecific polyclonal and monoclonal antibodies that allows for differentiation of TPH1 and TPH2 in immunoblotting, immunoprecipitation, and immunocytochemical staining. 

 

Commercial Applications:

  • Research agents used to differentiate between TPH1 and TPH2

 

Stage of Development:

Preclinical

 

Competitive Advantages:

  • Allows for studies of differential regulation of TPH1 and TPH2 expression in the brain and periphery

 

Intellectual Property Status:

No patent information available

 

Related Publications or Citations of Work:

None

Patent Information:
For Information, Contact:
Joan Dunbar
Associate Vice President for Technology Commercialization
Wayne State University
(313) 577-5542
jcdunbar@med.wayne.edu
Inventors:
Donald Kuhn
Keywords:
Antibody
Assay
Immunoassay